These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38828548)

  • 21. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
    Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
    Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
    Lin Q; Kolak M; Watts B; Anselin L; Pollack H; Schneider J; Taylor B
    Soc Sci Med; 2022 Jul; 305():115034. PubMed ID: 35636049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 28. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
    Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
    J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity.
    Ross RK; Inose S; Shulman M; Nunes EV; Zalla LC; Burlew AK; Rudolph KE
    JAMA Netw Open; 2024 Oct; 7(10):e2436612. PubMed ID: 39365581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder.
    Dever JA; Hertz MF; Dunlap LJ; Richardson JS; Wolicki SB; Biggers BB; Edlund MJ; Bohm MK; Turcios D; Jiang X; Zhou H; Evans ME; Guy GP
    Public Health Rep; 2024; 139(4):484-493. PubMed ID: 38268479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
    Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
    Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections.
    Ivasiy R; Madden LM; DiDomizio E; Johnson KA; Machavariani E; Ahmad B; Oliveros D; Ram A; Kil N; Altice FL
    Drug Alcohol Depend; 2024 Oct; 263():112410. PubMed ID: 39159600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
    Andraka-Christou B; Page C; Schoebel V; Buche J; Haffajee RL
    Addict Sci Clin Pract; 2022 Aug; 17(1):43. PubMed ID: 35945636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
    Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
    J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.
    Weiner SG; Little K; Yoo J; Flores DP; Hildebran C; Wright DA; Ritter GA; El Ibrahimi S
    JAMA Netw Open; 2024 Jul; 7(7):e2423954. PubMed ID: 39037812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
    Michener PS; Evans EA; Ferguson WJ; Friedmann PD
    Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.